symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
IGXT,0.129,2.361216,55181,22530882,0,0.1-0.27,-0.0058,IntelGenx Technologies Corp.,USD,0001098880,US45822R1014,45822R101,Other OTC,PNK,Biotechnology,https://www.intelgenx.com,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.","Mr. Andr√©  Godin C.A., CPA, CA, CPA",Healthcare,CA,48,514 331 7440,6420 Abrams,Montreal,QC,H4S 1Y2,,0,https://financialmodelingprep.com/image-stock/IGXT.png,2007-01-17,False,False,True,False,False
